The authors observed that EVs containing either survivin-T34A alone or in combination with gemcitabine increased apoptosis in multiple pancreatic cancer cell lines, as well as enhanced the sensitivity of these cells to gemcitabine. This evidence concerns the gene BIRC5 and pancreatic neoplasm.